Multiple Therapies, One Virus.
KALIVIR is developing cutting-edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. We design safe and potent oncolytic product candidates to treat patients across mulltiple tumor types. Learn more about us
PRESENTATIONS – Novel Vaccinia Enhanced Template (VET) Oncolytic Platform NEWS AND EVENTS
May –23, 2022 – KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses